Regeneron Pharmaceuticals Inc (REGN)

[DewDiligence]

NVS’ wet-AMD drug, RTH258 hits primary endpoint in phase-2 trial:

#msg-111253341

[jimmybob]

$REGN reports Q4 EPS $2.79, consensus $2.82
Reports Q4 revenue $802.33M, consensus $781.52M

[General Grievous]

fwiw...i just enrolled in the phase 3 trial for the drug Dupilumab...i hope i get it and not the placebo i really need it....

[jimmybob]

Regeneron upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Regeneron to Overweight with a $485 price target following recent survey results that indicates robust DME penetration for Elea. The analyst raised its Eylea 2015 estimate to 2.4B and 2016 to $2.7B and sees additional catalysts from further dupilumab data and Eylea ang2/PDGF combo data, and alirocumab approvals

[maytepper]

Deutsche Bank Maintains Buy On Regeneron Following Discussion With CEO

http://www.smarteranalyst.com/2014/12/02/deutsche-bank-maintains-buy-on-regeneron-following-discussion-with-ceo/

[maytepper]

Roth Capital Reiterates Buy On Regeneron Following Priority Review Acceptance http://www.smarteranalyst.com/2014/12/01/roth-capital-reiterates-buy-on-regeneron-following-priority-review-acceptance/

[jimmybob]

Regeneron announced FDA accepted review for sBLA for EYLEA injection
Regeneron announced that the FDA has accepted for priority review the supplemental biologics license application for EYLEA Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema. Under the Prescription Drug User Fee Act, the goal for a priority review is six months, for a target action date of March 30, 2015. In September 2014, the FDA granted EYLEA Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with DME. The FDA created the Breakthrough Therapy designation to expedite the development and review of drugs for serious or life-threatening conditions. The Phase 3 VIVID-DME and VISTA-DME trials, which supported the approval of EYLEA in DME, included a pre-specified secondary endpoint evaluating diabetic retinopathy based on an established grading scale in patients with DME. The two-year results from these trials on the primary endpoint of best-corrected visual acuity and overall safety have been previously reported

[Liam859]

Making new 52week highs!$$$$

[TREND1]

REGN D

[Liam859]

Look at that 3 yr chart... So beautiful

[maytepper]

$REGN Roth Capital Maintains Buy On Regeneron Following Eylea FDA Approval http://www.smarteranalyst.com/2014/10/07/roth-capital-maintains-buy-regeneron-following-eylea-fda-approval/

[stocktrademan]

$REGN DD Notes ~ http://www.ddnotesmaker.com/REGN

bullish long term investor buy and hold
dollar cost averaging, buy some each month purchase methods, etc...

$REGN recent news/filings

## source: finance.yahoo.com

Thu, 02 Oct 2014 19:33:00 GMT ~ Cholesterol Drugs Haunted By Ghosts Of Past, Present, And Future


read full: http://www.forbes.com/sites/larryhusten/2014/10/02/cholesterol-drugs-haunted-by-ghosts-of-past-present-and-future/?partner=yahootix
*********************************************************

Wed, 01 Oct 2014 23:52:00 GMT ~ Alibaba Among 5 Stocks With Superior Long-Term Growth


read full: http://news.investors.com/100114-719905-alibaba-gopro-top-stocks-with-strong-earnings-sales.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Wed, 01 Oct 2014 21:00:00 GMT ~ Why October could be bad for biotech

[Talking Numbers] - http://l.yimg.com/hv/api/res/1.2/OP9H_i06LQvRMU8bJ8PhOA--/YXBwaWQ9eWZpbmFuY2U7aD0zMTt3PTQy/http://l.yimg.com/os/en-US/video/video.pd2upload.com/video.tncnbc.com@a1ad4509-2d80-3112-a3c4-b525b395d709_FULL.jpg

read full: http://finance.yahoo.com/blogs/talking-numbers/why-october-could-be-bad-for-biotech-130332241.html
*********************************************************

Tue, 30 Sep 2014 19:04:00 GMT ~ Stocks Move To Session Lows; Regeneron Rises On Drug Data


read full: http://news.investors.com/093014-719590-ebay-outperforms-on-news-of-paypal-spinoff.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Tue, 30 Sep 2014 17:31:00 GMT ~ [video] Q4 momentum


read full: http://video.cnbc.com/gallery/?video=3000315851&__source=yahoo%7cheadline%7cquote%7cvideo%7c&par=yahoo
*********************************************************


$REGN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$REGN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/REGN/company-info
Ticker: $REGN
OTC Market Place: Not Available
CIK code: 0000872589
Company name: Regeneron Pharmaceuticals, Inc.
Incorporated In: NY, USA


$REGN share structure

## source: otcmarkets.com

Market Value: $35,045,935,310 a/o Oct 02, 2014
Shares Outstanding: 99,086,588 a/o Jul 17, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$REGN extra dd links

Company name: Regeneron Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/REGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/REGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=REGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=REGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=REGN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/news - http://finance.yahoo.com/q/h?s=REGN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/REGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/REGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/REGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/REGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=REGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/REGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Regeneron+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Regeneron+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Regeneron+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/REGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/REGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/REGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/REGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/REGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/REGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=REGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=REGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=REGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=REGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=REGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=REGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=REGN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/REGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=REGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/REGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=REGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/REGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/REGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/REGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/REGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/REGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=REGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=REGN



$REGN DD Notes ~ http://www.ddnotesmaker.com/REGN

[maytepper]

$REGN Roth Capital Reiterates Buy On Regeneron Pharmaceuticals Following Positive Trial Results http://www.smarteranalyst.com/2014/10/01/roth-capital-reiterates-buy-regeneron-pharmaceuticals-following-positive-trial-results/

[OGSPECULATOR]

Volume signal short term lower long term run!!!

[Arnold25764]

Wow, 350 bucks a share here

[Liam859]

My baby REGN :)

[maytepper]

Roth Capital Reiterates Buy On Regeneron Following 2Q14 Results; Keeps $399 Price Target http://www.smarteranalyst.com/2014/08/06/roth-capital-reiterates-buy-on-regeneron-following-2q14-results-keeps-399-price-target/

[Cast Iron]

I have started a New Board called -

OPTION TRADING ON EARNINGS

I have today made my first post on REGN

you are all welcome to look in and post

[OGSPECULATOR]

REGN is a buy!!!

[OGSPECULATOR]

Buy today!!!$$$

[starbuxsux]

Thank you...looks like the pre market traders knew that as well lol

[DewDiligence]

The Eylea data released today are from the 2-year follow-up; the primary endpoint of the Eylea DME trials was visual acuity at one year.

[starbuxsux]

Regeneron, Bayer Announce Results From Phase 3 VISTA Trial Of EYLEA

http://www.rttnews.com/Story.aspx?Id=2266444

[$A-Train]

Dip today, but I missed it.

[$A-Train]

The best phrase for REGN holders seems to be "'buy the dip"".

[Liam859]

Been livin this from a dolla 60

[surf1944]

6:15AM Regeneron Pharms and Bayer (BAYRY) reported earlier positive one-year results from two Phase 3 trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema (REGN) 270.99 : Co and Bayer HealthCare (BAYRY) announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity (BCVA) from baseline compared to laser photocoagulation at 52 weeks. Both EYLEA treatment arms demonstrated similar improvements in BCVA. Based on discussions with the FDA, Regeneron now expects to submit an application for U.S. marketing approval for the treatment of DME in 2013, ~ one year ahead of the previously announced timeline. Bayer Healthcare plans to submit an application for marketing approval for the treatment of DME in Europe in 2013.

In these trials, EYLEA was generally well tolerated with a similar overall incidence of adverse events (AEs), ocular serious AEs, and non-ocular serious AEs across the treatment groups and the laser control group. Arterial thromboembolic events as defined by the Anti-Platelet Trialists' Collaboration (non-fatal stroke, non-fatal myocardial infarction, and vascular death) also occurred at similar rates across the treatment groups and the laser control group.

covered short position

[ECole]

Goldman-Sachs Healthcare-Conference

Presentation at Goldman-Sachs-34th-Annual-Global-Healthcare-Conference..
Read here
REGN

[ChartHunter5]

New article compares Regeneron
http://seekingalpha.com/article/1344571-opko-health-this-biotech-short-bites-back

[AirCorps]

Any opinions as to what is an attractive entry point for this company?

[onarun]

Hope we see $200 and maybe a split

[boo boo]

Liking the intraday swings in this one. Pulled $3 from it so far today. Shake that a$$ maker.

[surf1944]

3:16AM Regeneron Pharms EYLEA injection approved for the treatment of Wet Age-Related Macular Degeneration in Europe (REGN) 174.39 : Co announces that EYLEA injection has been approved by the European Commission for the treatment of patients with neovascular age-related macular degeneration. EYLEA was approved for the treatment of neovascular AMD in the United States in November 2011 and in Japan, Australia, Switzerland, and other countries this year. Bayer HealthCare (BAYRY) plans to launch EYLEA in these countries later in 2012 and into 2013. In the United States, EYLEA was also approved for the treatment of Macular Edema following Central Retinal Vein Occlusion in September 2012

[onarun]

Did a search and this company came up...........should be $200+pps

[surf1944]

4:15AM Regeneron Pharms receives approval for EYLEA Injection for the Treatment of Wet Age-Related Macular Degeneration in Japan (REGN) 151.20 : Co announces that EYLEA Injection has received approval for the treatment of patients with neovascular age-related macular degeneration from the Japanese Ministry of Health, Labour and Welfare. The MHLW approval of EYLEA is based upon the results of two Phase 3 clinical studies which demonstrated that EYLEA dosed every other month, following three initial monthly doses was clinically equivalent to Lucentis dosed every four weeks, as measured by the proportion of patients who maintained visual acuity over 52 weeks, the primary endpoint of both studies. The most common adverse reactions (5.0% or more) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, vitreous detachment, cataract, vitreous floaters, and increased intraocular pressure. Bayer (BAYRY) HealthCare and Regeneron are collaborating on the global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in the United States. Bayer HealthCare has licensed the exclusive marketing rights outside the United States, where the companies will share equally the profits from any future sales of EYLEA, except for Japan where Regeneron will receive a royalty on net sales. In Japan, Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, has entered into a co-promotion agreement for EYLEA, with Santen Pharmaceutical.

[DewDiligence]

AGN inks new DARPin collaboration with Molecular Partners: #msg-78745948.

[MiamiGent]

REGN FDA rejects expanded use of Regeneron drug for gout
BY Reuters 9:44 PM ET 07/30/2012

http://stockcharts.com/h-sc/ui?s=REGN

July 30 (Reuters) - Regeneron Pharmaceuticals Inc (REGN) said U.S. regulators have denied approval for it to expand use of its Arcalyst drug to prevent gout flares, asking that the company provide more clinical data.

The rejection follows a unanimous vote against the drug's approval in early May by advisors to the U.S. Food and Drug Administration, with panel members expressing concern that the company had only done a 16-week study.

The agency has requested additional clinical data, including chemistry, manufacturing and controls information related to a proposed new dosage form for the injectable drug, Arcalyst, Regeneron said in a statement.

Regeneron, which had pitched Arcalyst for approval to treat gout flares in patients starting uric acid-lowering therapy, said it was reviewing the FDA's requests.

Patients afflicted with gout experience severe pain and inflammation due to deposits of uric acid -- a body waste product -- in the joints and soft tissues.

Known generically as rilonacept, Arcalyst is already on the market to treat a group of rare genetic auto-inflammatory diseases. It only contributes modestly to Regeneron's overall sales.

Regeneron is better known for its recently approved Eylea to treat macular degeneration, the leading cause of blindness in the elderly. Arcalyst brought in sales of $6 million in the April-June period, while Eylea's sales shot up 57 percent to $194 million.

New York-based Regeneron's shares closed at $135.47 on Monday on the Nasdaq. (Reporting by Zeba Siddiqui in Bangalore and by Ransdell Pierson in New York; Editing by Andre Grenon and Edwina Gibbs)

[surf1944]

6:40AM Regeneron Pharms beats by $0.45, beats on revs (REGN) 121.44 : Reports Q2 (Jun) earnings of $0.90 per share, $0.45 better than the Capital IQ Consensus Estimate of $0.45; revenues rose 181.5% year/year to $304 mln vs the $255.08 mln consensus. Non-GAAP net income excludes non-cash share-based compensation expense and non-cash interest expense related to the Company's convertible senior notes. "Based on the results to date, we now forecast 2012 U.S. EYLEA net product sales of $700 to $750 million and expect to be profitable for the full year. We look forward to marketing approvals and launch of EYLEA outside the U.S. by our collaborator, Bayer HealthCare (BAYRY), during the second half of the year. We also await the September 23, 2012 PDUFA date for an FDA decision on our application to market EYLEA in the U.S. for the treatment of central retinal vein occlusion (CRVO), which would be in addition to our already approved EYLEA indication in the U.S. for neovascular age-related macular degeneration (wet AMD)."

[surf1944]

1:09AM Regeneron Pharms and Sanofi (SNY) receives Priority Review of the Biologics License Application for the investigational agent ZALTRAP from the FDA (REGN) 6.22 :

[Willsmith3]

Anyone know why this just keeps dropping and dropping? Should I get out and take my loss? Will it go back up? Any info I would be thankful for

[surf1944]

REGN looks as if it was a short on yesterdays gap up, you have to believe for now all the good news is in(short sell - trade only)

[Penny Roger$]

That is huge.. ^ 12%! My source said Thursday for earnings.. Might get a new source after board creation is all done.

[Penny Roger$]

~ Thursday! $REGN ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $REGN ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=REGN&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=REGN&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=REGN
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=REGN#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=REGN+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=REGN
Finviz: http://finviz.com/quote.ashx?t=REGN
~ BusyStock: http://busystock.com/i.php?s=REGN&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=REGN >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[Fossil-Fuel]

This thing's a beast! Do you see a top soon? I still think she's over valued even with the upgraded forecast market cap pushing 11 billion...

[surf1944]

7:13AM Regeneron Pharms beats by $0.23, misses on revs; raises FY12 EYLEA sales forecast (REGN) 102.08 : Reports Q4 (Dec) loss of $0.37 per share, $0.23 better than the Capital IQ Consensus Estimate of ($0.60); revenues fell 8.0% year/year to $123 mln vs the $129.18 mln consensus. Co sees Full Year 2012 EYLEA US sales increased to $250-300 mln from $140-160 mln prior guidance

[Fossil-Fuel]

Yeah I got hosed on that gap up from 65 to 75. Still watching tho definitaly looks top heavy.

[spartex]

I think you need to reassess. $66 ---> $100+, 33% gain in one month. May "now" be ripe for some puts as a side bet.

[Fossil-Fuel]

Yeah I saw that, insiders have been selling all year from what Etrade is showing. I picked up some puts here last Friday, looks like that run ran out of steam. imo

[surf1944]

Analyzing Friday's Noteworthy Insider Buys And Sells

http://seekingalpha.com/article/318057-analyzing-friday-s-noteworthy-insider-buys-and-sells?source=yahoo

[SoonerBrn]

Looks like this one could get interesting real soon.....